August 10, 2022

Breast-Cancer Pill Reduced Recurrence, Death in Early-Stage Patients, Study Finds

A drug sold by

AstraZeneca

AZN 0.27%

PLC and

Merck

MRK 2.16%

& Co. reduced the recurrence of breast cancer in women with an early but aggressive form of the disease, a long-running international study found.

The finding, which on Thursday was published online by the New England Journal of Medicine and released at a major cancer-research meeting, marked the latest advance in cancer treatments targeting the genetic traits of tumors. It could expand the arsenal of weapons against a hereditary form of breast cancer.

The result also helps validate the pharmaceutical industry’s investment in a pricey new class of drugs that target cancer cells, known as PARP inhibitors.

AstraZeneca’s pill, named Lynparza, has become one of the company’s top sellers, generating $1.8 billion in sales last year. Rival

GlaxoSmithKline

PLC paid more than $5 billion in 2019 to acquire the maker of another PARP inhibitor, Tesaro.

Lynparza carries a U.S. list price of about $14,449 per patient monthly.

AstraZeneca plans to submit the data to regulators and request regulatory approval of the use of Lynparza for early-stage BRCA breast cancer, said David Fredrickson, executive vice president of AstraZeneca’s oncology unit.

SHARE YOUR THOUGHTS

How optimistic are you about the new class of drugs known as PARP inhibitors for the treatment of breast cancer and other cancers? Join the conversation below.

PARP inhibitors work by blocking cancer cells from relying on a survival tactic: the ability to repair their own DNA after their DNA is damaged naturally or by other drug treatments. This, in turn, contributes to cancer-cell death.

Health regulators have approved these types of drugs in recent years to treat ovarian, breast, prostate and pancreatic cancers.

The drugs have been found to be particularly useful against cancers associated with harmful mutations in genes known as BRCA1 and BRCA2. Women with these hereditary mutations have a higher risk of developing breast cancer, and often at a younger age than is typical.

The BRCA mutations account for about 5% of the estimated 281,000 cases of breast cancer diagnosed annually in the U.S.

Overall, breast cancer is the second leading cause of cancer death in women, causing about 43,600 deaths in the U.S. annually, according to the American Cancer Society.

The Food and Drug Administration cleared Lynparza, in 2018, to treat advanced-stage BRCA-mutated breast cancer.

The new study tested Lynparza in women at earlier stages of breast cancer, at a time when it is potentially curable. AstraZeneca sponsored the study and collaborated with Merck and various research groups that run breast-cancer clinical trials.

Starting in 2014, researchers in the U.S. and 22 other countries enrolled 1,836 women with early-stage BRCA1 or BRCA2 breast cancer.

Before enrolling in the study, the women had undergone surgery to remove tumors, and had received chemotherapy before or after surgery aimed at preventing a recurrence of the tumor. They were at high risk of recurrence based on the size of their tumors or presence of cancer in lymph nodes.

The women also tested negative for the HER2 gene that is present in some breast cancers.

Half of the women in the study were randomly assigned to take Lynparza tablets daily for one year, while the other half got a placebo.

At a median follow-up period of 2½ years after the start of treatment, Lynparza reduced the combined risk of recurrence of cancer or death from any cause by 42% compared with a placebo, the researchers found.

Researchers estimated that three years after the start of treatment, 85.9% of the women who received Lynparza were living without disease recurrence, compared with 77.1% of women who received a placebo.

Lynparza tablets. The drug carries a U.S. list price of about $14,449 per patient monthly.



Photo:

AstraZeneca

Lynparza also improved other measures of benefit, including the time from the start of treatment until the development of tumors distant from the original site in the breasts.

There were fewer deaths among the Lynparza patients than among women who received the placebo, 59 versus 86, but the difference didn’t meet the study’s criteria for statistical significance at the time of follow-up.

Researchers said it may be possible at future dates to demonstrate a statistically significant improvement in overall survival.

“The early results are very encouraging that these therapies may indeed result in increased cures for patients who develop cancers with these mutations,” said Dr. Charles Geyer, deputy director of the Houston Methodist Cancer Center and one of the study’s leaders.

The presence of BRCA mutations can be detected with a blood test. “This further highlights the importance of genetic testing in appropriate patients, so that we know which patients will benefit from this therapy,” ASCO President Dr. Lori J. Pierce said in an online briefing with reporters.

Patients receiving Lynparza had higher rates of certain adverse events including nausea, fatigue and anemia, compared with those who received placebo, the study found. Researchers said this was consistent with the safety profile of the drug for other uses.

AstraZeneca had previously disclosed in February that the study was positive but didn’t report the full results until Thursday, ahead of being presented at the annual meeting of the American Society of Clinical Oncology. The New England Journal of Medicine also simultaneously published the results online.

AstraZeneca initially developed the drug. In 2017, it formed a partnership with Merck to further develop and co-market the drug.

Cancer drugs

Related coverage, selected by the editors

Write to Peter Loftus at [email protected]

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related Posts

Activist Investor Elliott Pushes Shake-Up at GlaxoSmithKline

July 1, 2021

July 1, 2021

Activist investor Elliott Management Corp. has intensified pressure on GlaxoSmithKline PLC, calling on the pharmaceutical giant to replace members of...

Trump’s TikTok, WeChat Actions Targeting China Revoked by Biden

June 9, 2021

June 9, 2021

WASHINGTON—President Biden revoked a Trump -era attempt to ban Chinese-owned apps TikTok and WeChat, substituting Wednesday an executive order mandating...

Fed’s Williams Says Economy Far From Levels Needed to Pare Stimulus

June 3, 2021

June 3, 2021

Federal Reserve Bank of New York leader John Williams said Thursday the U.S. economy remains some distance from where it...

Colonial Pipeline Missed Requested Security Review Before Hack

May 26, 2021

May 26, 2021

Colonial Pipeline Co. last year didn’t undergo a requested federal security review of its facilities and was in the process...

WhatsApp Says It Filed Suit in India to Prevent Tracing of Encrypted Messages

May 26, 2021

May 26, 2021

Facebook Inc.’s FB 0.97% WhatsApp said it filed a lawsuit in India to stop new government rules that would require...

What Working From Home Taught Us About Our Office Setups

June 6, 2021

June 6, 2021

Gabe Marans, an executive managing director at the real-estate company Savills, is back in his office on Park Avenue in...

UPS Explores Same-Day Delivery Option

June 9, 2021

June 9, 2021

United Parcel Service Inc. UPS -4.15% is exploring a same-day option, a delivery model that has been employed by gig-economy...

Harvard, MIT Part of $800 Million Deal to Push Access to Online Education

June 29, 2021

June 29, 2021

Education-technology company 2U Inc., which runs graduate programs for dozens of top universities, is buying web-based course provider edX, a...

U.S. Plans to Spend Big on Critical Minerals; Choosing Where Isn’t Easy

June 20, 2021

June 20, 2021

As the U.S. and its allies chase China in procuring critical minerals essential for modern technologies, they face a major...

Jobless Claims Rose Last Week, Pausing Downward Trend

June 17, 2021

June 17, 2021

Worker filings for initial unemployment benefits rose by 37,000 to 412,000 last week, marking the first increase since late April...

Don’t Sweat Your Pandemic Résumé Gap

June 21, 2021

June 21, 2021

Looking to get back to work after a pandemic break? That gap on your résumé might not be the obstacle...

Uber, Lyft Sweeten Job Perks Amid Driver Shortage, Lofty Fares

July 2, 2021

July 2, 2021

A shortage of drivers in the U.S. is propelling prices for Uber and Lyft LYFT 0.58% rides to record highs...

Lordstown Motors Executives Resign Amid Inaccurate Preorder Disclosures

June 14, 2021

June 14, 2021

Lordstown Motors Corp. RIDE -17.56% said its chief executive and top financial leader have resigned, decisions that come amid a...

Air Travel Returned. So Did Long Lines at Security, Restaurants, Shops.

June 18, 2021

June 18, 2021

Air travel has come roaring back. Not everyone was ready. Customers are facing hourslong phone waits for assistance. Long lines...

Troubled Companies Take Page From AMC Playbook in Seeking Stock-Market Lifelines

June 20, 2021

June 20, 2021

The frenzied stock-buying activity that may have saved AMC Entertainment Holdings Inc. from bankruptcy is opening up a potential escape...